EA
CLVS

Edge Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Edge Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$20K Hold
450
– – ﹤0.01% 642
2018
Q1 		$23K Hold
450
– – ﹤0.01% 632
2017
Q4 		$30K Buy
450
+200
+80% +$14K ﹤0.01% 618
2017
Q3 		$20K Hold
250
– – ﹤0.01% 660
2017
Q2 		$23K Buy
+250
New +$15.3K ﹤0.01% 649

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Edge Advisors's CLVS Position: Q2 2018 in Review

Edge Advisors held its Clovis Oncology, Inc. (CLVS) position steady in Q2 2018 at 450 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #642.

Edge Advisors first reported a position in CLVS in Q2 2017 and has held it in 5 quarters since. The position peaked at $30K in Q4 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • Edge Advisors held 450 shares of Clovis Oncology, Inc. worth $20K as of Q2 2018.
  • Edge Advisors left its Clovis Oncology, Inc. share count unchanged in Q2 2018.
  • Clovis Oncology, Inc. made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #642 holding.
  • Edge Advisors first reported a position in Clovis Oncology, Inc. in Q2 2017 and has held it in 5 quarters since.
  • Edge Advisors's Clovis Oncology, Inc. position peaked at $30K in Q4 2017.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.